Recursion Pharmaceuticals Inc

RXRX remains entrenched in a Stage 4 decline with a persistent lower-highs/lower-lows sequence and a decisive support failure. Medium-term bias prohibits bullish engagement, as price trades below declining 9/21 EMAs and major moving averages. Volume has expanded on down moves and RSI remains near oversold without divergence, indicating accelerating supply. Short-term momentum aligns with the medium-term downtrend, offering a selling opportunity now into any brief relief rally toward broken support-turned-resistance.

• ↑ARK Invest acquired 260k shares, reaffirming AI-driven pipeline appeal
• ↑Q1 2026 cash at $754M supports growth initiatives, runway to early 2028
• ↓35.1% short interest indicates significant bearish conviction in fundamentals